Back to top
more

Cytokinetics, Incorporated (CYTK)

(Delayed Data from NSDQ)

$6.49 USD

6.49
304,055

+0.32 (5.19%)

Updated Nov 15, 2018 04:00 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
25.32%
18.25%
9.79%
5.22%
2.14%
10.57%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | C Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Balance Sheet

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for CYTK

 

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Fiscal Year End for Cytokinetics, Incorporated falls in the month of December.

All items in Millions except Per Share data.

12/31/2017 12/31/2016 12/31/2015 12/31/2014 12/31/2013
Assets          
Cash & Equivalents 269 156 111 83 78
Receivables 1 0 0 0 0
Notes Receivable 0 0 0 47 0
Inventories 0 0 0 0 0
Other Current Assets 4 2 2 1 2
Total Current Assets 274 159 113 131 79
Net Property & Equipment 4 4 2 2 1
Investments & Advances 17 8 0 0 3
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 0 0 0 0 0
Total Assets 295 170 115 133 83
Liabilities & Shareholders Equity 12/31/2017 12/31/2016 12/31/2015 12/31/2014 12/31/2013
Notes Payable 0 0 0 0 0
Accounts Payable 5 4 2 1 4
Current Portion Long-Term Debt 0 3 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 17 18 8 5 8
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 10 8 21 17 15
Total Current Liabilities 32 33 32 24 27
Mortgages 0 0 0 0 0
Deferred Taxes/Income 15 15 0 17 2
Convertible Debt 0 0 0 0 0
Long-Term Debt 32 27 15 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 106 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 185 76 47 41 29
Shareholders Equity 12/31/2017 12/31/2016 12/31/2015 12/31/2014 12/31/2013
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 756 612 603 589 537
Retained Earnings -646 -518 -535 -497 -483
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 110 94 69 92 54
Total Liabilities & Shareholder's Equity 295 170 115 133 83
Total Common Equity 110 94 69 92 54
Shares Outstanding 53.80 40.60 38.80 36.60 29.50
Book Value Per Share 2.04 2.32 1.77 2.52 1.85

Fiscal Year End for Cytokinetics, Incorporated falls in the month of December.

All items in Millions except Per Share data.

9/30/2018 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Assets          
Cash & Equivalents 210 232 251 269 308
Receivables NA 0 0 1 10
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets 17 12 21 4 4
Total Current Assets 227 244 272 274 322
Net Property & Equipment 3 3 3 4 3
Investments & Advances NA 0 4 17 1
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets 0 0 0 0 0
Total Assets 230 247 280 295 326
Liabilities & Shareholders Equity 9/30/2018 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Notes Payable NA 0 0 0 0
Accounts Payable 18 1 2 5 4
Current Portion Long-Term Debt 4 2 0 0 10
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 16 16 17 18
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities 0 8 21 10 10
Total Current Liabilities 21 27 39 32 42
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 15 16
Convertible Debt NA 0 0 0 0
Long-Term Debt 38 31 32 32 20
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities 119 110 106 101
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities 178 172 180 185 179
Shareholders Equity 9/30/2018 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Preferred Stock NA 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 766 763 757 756 752
Retained Earnings -714 -688 -658 -646 -606
Other Equity 0 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity 52 75 100 110 147
Total Liabilities & Shareholder's Equity 230 247 280 295 326
Total Common Equity 100,051 75 100 110 147
Shares Outstanding 54.60 54.60 54.00 53.80 53.60
Book Value Per Share 1,832.44 1.38 1.84 2.04 2.74